Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

<p>NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer’s and Parkinson’s diseases. The effect of two chemically distinct σ-2 receptor modulators in a mouse […]</p>
<p>The post <a href="https://forextv.com/top-news/cognition-therapeutics-presents-preclinical-data-identifying-pathways-impacted-by-sigma-2-receptor-modulators-in-alzheimers-and-parkinsons-diseases/">Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>